UNSPSC 51372035: Morphine oxide

This classification denotes an opiate with the molecular formula C17H19NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9E77NL2Y9I, chemically known as morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5.alpha.,6.alpha.)-, 17-oxide, but more generally known as morphine oxide, which bears US NIH Compound Identifier 5362459. European Medicines Agency schedules morphine oxide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03332MIG.

Most nations, for tariff purposes, schedule morphine oxide under HS 29391100. SMILES: C[N+]1(CC[C@]23C4C5CCC(C4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)O)[O-].

UNSPSC 51372035 Morphine oxide is a Commodity-level code that in recent state and local procurement activity encompasses opioid antagonists, pharmaceutical supply chain services, and generic multi-source pharmaceutical distribution—a broader scope than the code name alone suggests. State and local governments procuring under this code are acquiring naloxone and safe drug deactivation systems for community health and overdose response, generic pharmaceuticals and over-the-counter products through cooperative purchasing arrangements, and direct-to-manufacturer prescription fulfillment programs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and state procurement offices administering multistate cooperative purchasing alliances (Minnesota Department of Administration via MMCAP).

Recent activity spans Florida, Texas, and Minnesota, with MMCAP's multistate vehicle extending reach to Oregon and other participating jurisdictions. Representative current opportunities include Seminole County's IFB 60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline; Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, soliciting vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program with the same-day April 3, 2026 response deadline; and Minnesota's MMCAP RFP S1070000015802, posted January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline and July 1, 2026 contract effective date. MMCAP's RFP requires manufacturers to work through three authorized wholesalers, certify cGMP and Drug Supply Chain Security Act compliance, and accept 3 percent administrative fees and performance penalties of $200 to $1,500 per violation. Naloxone procurement carries FEMA funding potential and standard procurement compliance including drug-free workplace certification and E-Verify requirements.